1. Home
  2. CFND vs BDSX Comparison

CFND vs BDSX Comparison

Compare CFND & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$4.98

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$8.00

Market Cap

62.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
BDSX
Founded
N/A
2005
Country
United States
Employees
N/A
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
62.5M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
CFND
BDSX
Price
$4.98
$8.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
N/A
63.1K
Earning Date
N/A
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
N/A
$3.44
52 Week High
N/A
$32.20

Technical Indicators

Market Signals
Indicator
CFND
BDSX
Relative Strength Index (RSI) N/A 52.58
Support Level N/A $7.52
Resistance Level N/A $8.20
Average True Range (ATR) 0.00 0.56
MACD 0.00 -0.05
Stochastic Oscillator 0.00 45.61

Price Performance

Historical Comparison
CFND
BDSX

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: